Prescient’s Andrea Campi’s doctoral research has yielded a published article in Bone:

Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody

UCB and Amgen funded this research to investigate the effects of sclerostin antibody on live osteocytes in an ex vivo mouse bone model. Most recently, a monoclonal antibody to sclerostin (EVENITY, romosozumab-aqqg) gained approvals from the FDA and EC approval for the treatment of post-menopausal women at a high risk of osteoporotic fracture.

Click here to read the article